Windward Bio Group AG

Windward Bio Group AG

NNASDAQ:WWB
30.04
USD
+1.54
(+5.40%)
No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Semi-annual Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Semi-annual Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Semi-annual Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

CEO
Luca Santarelli
Full Time Employees
33
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Aeschenplatz 6 Basel BS Switzerland 4052
IPO Date
Nov 13, 2026
Business
Its lead programs target thymic stromal lymphopoietin and interleukin-13 and are in clinical development. Windward Bio Group AG is a Swiss clinical-stage biotechnology company founded in 2024 that develops ultra-long-acting monoclonal antibodies for serious respiratory and dermatologic immunological diseases, including asthma, chronic obstructive pulmonary disease, and atopic dermatitis.